No. 18: B. Braun Melsungen
Melsungen, Germany
2017 revenues: $7,671,457,000 (€6,788,900,000)
2017 R&D spend: $356,967,000
Fiscal year ending: December 31, 2017
Employees: 61,583
Key Personnel:
Heinz-Walter Große, Chairman, Chief HR Officer; Annette Beller, director, Finance, Taxes & Controlling, Central Service; Anna Maria Braun, director, President, Asia Pacific; Meinrad Lugan, director, Hospital Care , OutPatient; Caroll Neubauer, director, North America; Joachim Schulz, director, Aesculap; Markus Strotmann, director, Avitum
Description:
B. Braun’s Aesculap closed a $17.3 million deal in February to buy Dextera out of Chapter 11 bankruptcy. Braun itself inked a deal in early July to acquire NxStage Medical’s Medisystems bloodlines business, as part of the latter’s bid to mollify anti-trust regulators about its pending, $2 billion acquisition by Fresenius.